PDCD1 and neoplasm: In TNBC patients, significantly elevated concentrations of TMAO were observed in tumor tissues situated within immunologically active microenvironments, with this metabolite demonstrating the capacity to induce tumor cell pyroptosis and enhance CD8+ T cell‐mediated antitumor immune responses, thereby significantly improving patient responses to anti‐PD‐1 immunotherapy [207].